Medical News

Pfizer Drops Development of Antiretroviral Capravirine, Citing Lack of Efficacy in Trials

July 5, 2005

Pharmaceutical company Pfizer announced on Friday that it is stopping the development of two drugs, including one to treat HIV infection, Reuters reports (Clarke, Reuters, 7/4). The company said it is dropping the development of the antiretroviral capravirine because the drug in two studies did not significantly boost the efficacy of already-approved antiretroviral combinations among HIV-positive people who had failed to respond to those regimens. Pfizer plans to return the rights to capravirine to Shionogi & Co., the Japanese company that developed the compound. Pfizer will continue its late-stage trials of another antiretroviral drug called maraviroc, which is designed to prevent HIV from entering cells (Vogt, AP/San Francisco Chronicle, 7/1). Barbara Ryan, an analyst with Deutsche Bank, said capravirine would have produced peak sales of about $200 million if it had been approved, according to Reuters (Reuters, 7/4).

Back to other news for July 5, 2005

Reprinted with permission from You can view the entire Kaiser Daily HIV/AIDS Report, search the archives, or sign up for email delivery at The Kaiser Daily HIV/AIDS Report is published for, a free service of the Kaiser Family Foundation, by The Advisory Board Company. © 2004 by The Advisory Board Company and Kaiser Family Foundation. All rights reserved.

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.